March 15 (Reuters) - Orexigen Therapeutics Inc OREX.O said
it would pay $60 million to acquire the U.S. rights to its
flagship obesity drug from partner Takeda Pharmaceutical Co
4502.T .
Orexigen said it had also entered into a deal with Canada's
Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO to sell the
treatment in central and eastern Europe.